With obesity and diabetes rates climbing, distributors can position metabolic and gut health products in lifestyle-friendly dosage forms to capture growth in underpenetrated markets
Type 2 diabetes typically occurs when the body is not producing a sufficient amount of insulin, which keeps glucose in the bloodstream instead of being used as energy
GLP-1 receptor agonists act on a single incretin pathwaythe GLP-1 pathwayto regulate blood sugar and appetite
These benefits are updated and refined based on continuing feedback from team members across the system
The best course of action with any GLP-1 treatment is to continue your treatment plan for as long as possible to ensure you get maximum benefits
A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment